メインコンテンツにスキップ
検索

早期臨床

登録

最新のリソース

注目コンテンツ

Upcoming early clinical webinars

Latest early clinical blogs

医薬品開発におけるPK/PDモデリングのための機械学習
Machine Learning for PK/PD Modeling in Drug DevelopmentBlog

医薬品開発におけるPK/PDモデリングのための機械学習

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法
How the US FDA MIDD paired pilot program helps sponsorsBlog

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法

指標となる臨床的薬剤相互作用研究における代謝物の測定
Measuring metabolites in index clinical DDI studiesBlog

指標となる臨床的薬剤相互作用研究における代謝物の測定

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters
Why FDA’s omaveloxolone approval for Friedreich’s ataxia mattersBlog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Key development considerations for cell therapies
Key development considerations for cell therapiesBlog

Key development considerations for cell therapies

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ
De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development Blog

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ

以下のイベントで弊社のエキスパートをご紹介

All early clinical resources

The IQ-CSRC Prospective Clinical Phase 1 Study: Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Publication

Incorporating Target Shedding into a Minimal PBPK-TMDD Model for Monoclonal Antibodies

Model Informed Drug Development, pre-update, Publication

Anatomical, Physiological and Metabolic Changes with Gestational Age During Normal Pregnancy: A Database for Parameters Required in Physiologically-based Pharmacokinetic Modeling

Model Informed Drug Development, pre-update, Publication

Bottom-up Modeling and Simulation of Tacrolimus Clearance: Prospective Investigation of Blood Cell Distribution, Sex and CYP3A5 Expression as Covariates and Assessment of Study Power

Model Informed Drug Development, pre-update, Publication

An Evaluation of the Pharmacokinetics of Treprostinil Diethanolamine in Subjects with Hepatic Impairment

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Modeling of Pharmacokinetic Systems Using Stochastic Deconvolution

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Publication

Differences in Cytochrome P450-mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically-based Pharmacokinetic Modeling

Model Informed Drug Development, pre-update, Publication

Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Introduction to Population PK/PD Analysis Using Phoenix NLME

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, On-Demand Webinar

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication
ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。


Powered by Translations.com GlobalLink Web Software